- Published on
ReCode Therapeutics, cofounded by Dr. Daniel J. Siegwart, Raises Over $29M in Additional Financing
- Author
-
-
- Name
- Posts
- Posts
-
ReCode Therapeutics, a Menlo Park, CA-based clinical-stage genetic medicines company, raised over $29M in additional funding.
Backers were undisclosed.
It also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) and a new research collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX).
The company intends to use the funds to expand operations and its R&D efforts.
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. Its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables precise and targeted delivery of genetic medicines directly to the organs, tissues, and cells implicated in disease, enabling improved efficacy and potency.
Its lead programs include RCT2100 for the treatment of the 10% of people with cystic fibrosis who have genetic mutations in the CFTR gene that do not respond to currently approved CFTR modulators or those intolerant of approved CFTR modulators, and RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated with the SORT LNP delivery platform.
source; FinSMEs
Backers were undisclosed.
It also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) and a new research collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX).
The company intends to use the funds to expand operations and its R&D efforts.
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. Its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables precise and targeted delivery of genetic medicines directly to the organs, tissues, and cells implicated in disease, enabling improved efficacy and potency.
Its lead programs include RCT2100 for the treatment of the 10% of people with cystic fibrosis who have genetic mutations in the CFTR gene that do not respond to currently approved CFTR modulators or those intolerant of approved CFTR modulators, and RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated with the SORT LNP delivery platform.
source; FinSMEs
0 Comments